119.79
price up icon1.14%   1.35
pre-market  Pre-market:  119.42   -0.37   -0.31%
loading
Gilead Sciences Inc stock is traded at $119.79, with a volume of 9.94M. It is up +1.14% in the last 24 hours and up +7.92% over the past month. Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$118.44
Open:
$116.06
24h Volume:
9.94M
Relative Volume:
1.46
Market Cap:
$148.64B
Revenue:
$29.04B
Net Income/Loss:
$8.11B
P/E Ratio:
18.56
EPS:
6.4525
Net Cash Flow:
$9.37B
1W Performance:
-0.95%
1M Performance:
+7.92%
6M Performance:
+12.44%
1Y Performance:
+34.87%
1-Day Range:
Value
$114.02
$121.91
1-Week Range:
Value
$114.02
$121.91
52-Week Range:
Value
$86.08
$124.61

Gilead Sciences Inc Stock (GILD) Company Profile

Name
Name
Gilead Sciences Inc
Name
Phone
(650) 574-3000
Name
Address
333 LAKESIDE DR, FOSTER CITY, CA
Name
Employee
17,600
Name
Twitter
@GileadSciences
Name
Next Earnings Date
2025-02-11
Name
Latest SEC Filings
Name
GILD's Discussions on Twitter

Compare GILD with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
GILD
Gilead Sciences Inc
119.79 146.96B 29.04B 8.11B 9.37B 6.4525
Drug Manufacturers - General icon
LLY
Lilly Eli Co
862.86 757.06B 59.42B 18.41B -50.20M 20.22
Drug Manufacturers - General icon
JNJ
Johnson Johnson
188.87 455.48B 92.15B 25.12B 20.46B 10.36
Drug Manufacturers - General icon
ABBV
Abbvie Inc
218.04 403.13B 58.33B 3.73B 18.24B 2.1013
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
123.79 235.26B 54.45B 14.42B 17.15B 7.333
Drug Manufacturers - General icon
MRK
Merck Co Inc
85.98 215.51B 63.99B 19.05B 14.72B 7.5596

Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-19-25 Upgrade Daiwa Securities Neutral → Outperform
Aug-08-25 Upgrade Truist Hold → Buy
Jul-25-25 Upgrade Needham Hold → Buy
Apr-22-25 Resumed Cantor Fitzgerald Overweight
Mar-04-25 Reiterated Oppenheimer Outperform
Feb-18-25 Upgrade Deutsche Bank Hold → Buy
Feb-13-25 Upgrade DZ Bank Hold → Buy
Jan-10-25 Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-10-24 Resumed BofA Securities Buy
Nov-15-24 Initiated Wolfe Research Outperform
Nov-14-24 Initiated Citigroup Buy
Nov-08-24 Downgrade Maxim Group Buy → Hold
Oct-21-24 Upgrade Leerink Partners Market Perform → Outperform
Oct-17-24 Initiated Bernstein Outperform
Oct-07-24 Upgrade Wells Fargo Equal Weight → Overweight
Jul-08-24 Upgrade Raymond James Mkt Perform → Outperform
May-01-24 Reiterated Maxim Group Buy
Apr-24-24 Upgrade HSBC Securities Reduce → Hold
Feb-22-24 Downgrade Truist Buy → Hold
Nov-09-23 Initiated Deutsche Bank Hold
Sep-08-23 Upgrade BofA Securities Neutral → Buy
Sep-06-23 Initiated HSBC Securities Reduce
Jul-24-23 Reiterated Barclays Equal Weight
May-16-23 Upgrade BMO Capital Markets Market Perform → Outperform
Apr-28-23 Resumed Piper Sandler Overweight
Jan-03-23 Downgrade RBC Capital Mkts Outperform → Sector Perform
Dec-13-22 Resumed BofA Securities Neutral
Dec-09-22 Downgrade DZ Bank Buy → Hold
Oct-31-22 Upgrade Barclays Underweight → Equal Weight
Oct-28-22 Reiterated BMO Capital Markets Market Perform
Oct-28-22 Reiterated Cowen Outperform
Oct-28-22 Reiterated JP Morgan Overweight
Oct-28-22 Reiterated Jefferies Buy
Oct-28-22 Upgrade Piper Sandler Neutral → Overweight
Oct-28-22 Reiterated RBC Capital Mkts Outperform
Oct-28-22 Upgrade Truist Hold → Buy
Oct-28-22 Reiterated Wells Fargo Equal Weight
Oct-04-22 Upgrade JP Morgan Neutral → Overweight
Jul-13-22 Initiated Cantor Fitzgerald Neutral
May-23-22 Initiated SVB Leerink Mkt Perform
Feb-28-22 Downgrade BMO Capital Markets Outperform → Market Perform
Feb-02-22 Reiterated BMO Capital Markets Outperform
Feb-02-22 Reiterated BofA Securities Neutral
Feb-02-22 Reiterated RBC Capital Mkts Outperform
Feb-02-22 Reiterated Truist Hold
Feb-02-22 Reiterated Wells Fargo Equal Weight
Jan-28-22 Upgrade Argus Hold → Buy
Jan-06-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Dec-09-21 Resumed Wells Fargo Equal Weight
Dec-06-21 Initiated Goldman Neutral
Nov-19-21 Upgrade BMO Capital Markets Market Perform → Outperform
Nov-19-21 Resumed Piper Sandler Neutral
Oct-20-21 Resumed Cowen Outperform
Jul-30-21 Reiterated BMO Capital Markets Market Perform
Jul-30-21 Reiterated RBC Capital Mkts Outperform
Apr-01-21 Upgrade Bernstein Mkt Perform → Outperform
Mar-30-21 Upgrade Redburn Neutral → Buy
Jan-19-21 Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-04-21 Upgrade Guggenheim Neutral → Buy
Nov-03-20 Resumed Morgan Stanley Equal-Weight
Oct-28-20 Initiated UBS Neutral
Sep-30-20 Resumed Jefferies Buy
Sep-15-20 Upgrade Maxim Group Hold → Buy
Jul-31-20 Reiterated Credit Suisse Neutral
Jul-31-20 Reiterated Morgan Stanley Equal-Weight
Jul-31-20 Reiterated Piper Sandler Overweight
Jul-31-20 Reiterated RBC Capital Mkts Outperform
Jul-31-20 Reiterated SunTrust Hold
Jul-31-20 Reiterated Wells Fargo Equal Weight
Jul-20-20 Upgrade Credit Suisse Underperform → Neutral
Jun-03-20 Upgrade SVB Leerink Mkt Perform → Outperform
May-26-20 Upgrade SunTrust Sell → Hold
May-01-20 Downgrade JP Morgan Overweight → Neutral
May-01-20 Downgrade Raymond James Outperform → Mkt Perform
May-01-20 Downgrade SunTrust Hold → Sell
Apr-27-20 Downgrade UBS Buy → Neutral
Apr-20-20 Downgrade BMO Capital Markets Outperform → Market Perform
Apr-20-20 Downgrade Wells Fargo Overweight → Equal Weight
Apr-17-20 Downgrade CFRA Hold → Sell
View All

Gilead Sciences Inc Stock (GILD) Latest News

pulisher
06:28 AM

2,128 Shares in Gilead Sciences, Inc. $GILD Purchased by Elm Partners Management LLC - MarketBeat

06:28 AM
pulisher
03:24 AM

Real time alert setup for Gilead Sciences Inc. performanceQuarterly Profit Report & Community Verified Watchlist Alerts - newser.com

03:24 AM
pulisher
02:22 AM

What candlestick patterns are forming on Gilead Sciences Inc.Trade Signal Summary & Risk Adjusted Buy and Sell Alerts - newser.com

02:22 AM
pulisher
Nov 02, 2025

Longbow Finance SA Purchases 9,390 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Nov 02, 2025
pulisher
Nov 02, 2025

Syverson Strege & Co Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat

Nov 02, 2025
pulisher
Nov 02, 2025

NWK Group Inc. Has $7.33 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat

Nov 02, 2025
pulisher
Nov 02, 2025

Gilead Sciences, Inc. $GILD Shares Bought by Assetmark Inc. - MarketBeat

Nov 02, 2025
pulisher
Nov 02, 2025

Gilead Sciences, Inc. (NASDAQ:GILD) Q3 2025 Earnings Call Transcript - Insider Monkey

Nov 02, 2025
pulisher
Nov 01, 2025

Gilead Sciences, Inc. (GILD) Analyst insights, Price targets and Recommendations - Yahoo! Finance Australia

Nov 01, 2025
pulisher
Nov 01, 2025

Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat

Nov 01, 2025
pulisher
Nov 01, 2025

Gilead Sciences (NASDAQ:GILD) Price Target Raised to $105.00 at Royal Bank Of Canada - MarketBeat

Nov 01, 2025
pulisher
Nov 01, 2025

Gilead Sciences' (GILD) "Overweight" Rating Reaffirmed at Cantor Fitzgerald - MarketBeat

Nov 01, 2025
pulisher
Nov 01, 2025

Morgan Stanley Boosts Gilead Sciences (NASDAQ:GILD) Price Target to $147.00 - MarketBeat

Nov 01, 2025
pulisher
Nov 01, 2025

Gilead Sciences (NASDAQ:GILD) Price Target Raised to $145.00 - MarketBeat

Nov 01, 2025
pulisher
Nov 01, 2025

Gilead Sciences, Inc. (NASDAQ:GILD) Plans $0.79 Quarterly Dividend - MarketBeat

Nov 01, 2025
pulisher
Nov 01, 2025

Gilead Sciences (NASDAQ:GILD) Given New $110.00 Price Target at The Goldman Sachs Group - MarketBeat

Nov 01, 2025
pulisher
Nov 01, 2025

Gilead Sciences (NASDAQ:GILD) Earns "Buy" Rating from Needham & Company LLC - MarketBeat

Nov 01, 2025
pulisher
Nov 01, 2025

Wells Fargo Maintains Gilead Sciences (GILD) Overweight Recommendation - Nasdaq

Nov 01, 2025
pulisher
Nov 01, 2025

Fisher Funds Management LTD Reduces Position in Gilead Sciences, Inc. $GILD - MarketBeat

Nov 01, 2025
pulisher
Nov 01, 2025

Atria Investments Inc Purchases 14,392 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Nov 01, 2025
pulisher
Nov 01, 2025

Price momentum metrics for Gilead Sciences Inc. explainedTrade Analysis Report & Proven Capital Preservation Methods - newser.com

Nov 01, 2025
pulisher
Nov 01, 2025

JP Morgan Raises Gilead Sciences (GILD) Price Target to $150 | G - GuruFocus

Nov 01, 2025
pulisher
Oct 31, 2025

Gilead Sciences (NASDAQ:GILD) Posts Quarterly Earnings Results - MarketBeat

Oct 31, 2025
pulisher
Oct 31, 2025

Gilead Sciences (GILD) Profit Margin Surge Reinforces Bullish Narratives on Operational Turnaround - Yahoo Finance

Oct 31, 2025
pulisher
Oct 31, 2025

Needham Reiterates Gilead Sciences (GILD) Buy Recommendation - Nasdaq

Oct 31, 2025
pulisher
Oct 31, 2025

Gilead Sciences (NASDAQ:GILD) Updates FY 2025 Earnings Guidance - MarketBeat

Oct 31, 2025
pulisher
Oct 31, 2025

Gilead Stock Reverses; Why Its New HIV Shot Looks Better - Investor's Business Daily

Oct 31, 2025
pulisher
Oct 31, 2025

Research Alert: CFRA Keeps Buy Rating On Shares Of Gilead Sciences, Inc. - 富途牛牛

Oct 31, 2025
pulisher
Oct 31, 2025

Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026 - Benzinga

Oct 31, 2025
pulisher
Oct 31, 2025

RBC Capital Maintains Gilead Sciences (GILD) Rating, Raises Pric - GuruFocus

Oct 31, 2025
pulisher
Oct 31, 2025

Gilead’s long-acting PrEP Yeztugo takes off while cell therapy declines continue to haunt sales - Fierce Pharma

Oct 31, 2025
pulisher
Oct 31, 2025

Gilead Sciences: Strong Performance and Future Potential Drive Buy Rating - TipRanks

Oct 31, 2025
pulisher
Oct 31, 2025

Gilead's Cell Therapy Portfolio Slumps in Q3, but Firm Still Optimistic About In Vivo Opportunities - Precision Medicine Online

Oct 31, 2025
pulisher
Oct 31, 2025

GILD Q3 Earnings and Sales Beat Estimates, HIV and Livdelzi Sales Grow - TradingView

Oct 31, 2025
pulisher
Oct 31, 2025

HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead - Enidnews.com

Oct 31, 2025
pulisher
Oct 31, 2025

Does Gilead Sciences Offer Strong Value After Breakthroughs in Antiviral Treatments? - simplywall.st

Oct 31, 2025
pulisher
Oct 31, 2025

Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir) - BioSpace

Oct 31, 2025
pulisher
Oct 31, 2025

Gilead GILD Q3 2025 Earnings Call Transcript - AOL.com

Oct 31, 2025
pulisher
Oct 31, 2025

Gilead Sciences (GILD) Maintains Dividend, Adjusts 2025 Outlook - GuruFocus

Oct 31, 2025
pulisher
Oct 31, 2025

Gilead Sciences (GILD) Acquires Key Assets from HOOKIPA Pharma - GuruFocus

Oct 31, 2025
pulisher
Oct 31, 2025

Hookipa Pharma Completes Sales of HBV and HIV Assets to Gilead Sciences - MarketScreener

Oct 31, 2025
pulisher
Oct 31, 2025

Gilead 3rd-qtr EPS beats expectations - The Pharma Letter

Oct 31, 2025
pulisher
Oct 31, 2025

GILD Receives 'Buy' Rating Reiteration from Needham | GILD Stock News - GuruFocus

Oct 31, 2025
pulisher
Oct 31, 2025

GILD Q3 Deep Dive: HIV and Liver Disease Strength Offset Oncology Headwinds - Yahoo Finance

Oct 31, 2025
pulisher
Oct 31, 2025

Impact Partnership Wealth LLC Grows Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat

Oct 31, 2025
pulisher
Oct 31, 2025

HOOKIPA Pharma Inc. Completes Asset Sale of HB-400 and HB-500 Programs to Gilead Sciences - Quiver Quantitative

Oct 31, 2025
pulisher
Oct 31, 2025

Gilead Still Hungry for Deals as HIV Portfolio Grows, Veklury Crashes - BioSpace

Oct 31, 2025
pulisher
Oct 31, 2025

Amalgamated Bank Buys 22,916 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Oct 31, 2025
pulisher
Oct 31, 2025

Goldman Sachs Adjusts Price Target on Gilead Sciences to $110 From $108, Maintains Neutral Rating - MarketScreener

Oct 31, 2025
pulisher
Oct 31, 2025

Morgan Stanley Adjusts Price Target on Gilead Sciences to $147 From $143, Maintains Overweight Rating - MarketScreener

Oct 31, 2025
pulisher
Oct 31, 2025

Wells Fargo Adjusts Price Target on Gilead Sciences to $145 From $140, Maintains Overweight Rating - MarketScreener

Oct 31, 2025

Gilead Sciences Inc Stock (GILD) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_general PFE
$24.65
price up icon 1.48%
$298.43
price up icon 2.20%
drug_manufacturers_general NVO
$49.46
price down icon 1.16%
drug_manufacturers_general SNY
$50.58
price down icon 0.71%
drug_manufacturers_general MRK
$85.98
price down icon 0.35%
Cap:     |  Volume (24h):